Human tweak tnfsf12 kit dy1090

Serum concentrations of sTWEAK and sCD163 were determined by ELISA using the commercially available human TWEAK/TNFSF12 Kit DY1090, and human CD163 Kit DY1607 (R&D Systems Europe, Abingdon, Oxon, United Kingdom), respectively. The intra- and inter-assay coefficients of variation were 2.5 and 7.0% for sTWEAK and 2.4 and 6.4% for sCD163, respectively. Plasma omentin concentration was determined using a commercial omentin-1 human ELISA (BioVendor GmbH, Heidelberg, Germany). Plasma sCD14 was measured with a commercially available ELISA kit on sera diluted 0.01% (R&D Systems, Abingdon, UK). All ELISA assays were performed in duplicate.

All patients underwent anthropometric measurements. Blood was extracted for measurements of plasma lipids, glucose, insulin and sTWEAK after an 8-h fast. The glucose and lipid levels were determined by standard laboratory methods. Serum insulin was measured in duplicate using a monoclonal immunoradiometric assay (Medgenix Diagnostics, Fleunes, Belgium). The serum γ-glutamyltransferase (GGT), uric acid and creatinine levels were determined using enzymatic methods. The HOMA-IR index was calculated using the following formula:
Serum concentrations of sTWEAK were determined in duplicate by the enzyme-linked immunosorbent assay using the human TWEAK/TNFSF12 Kit #DY1090 (R&D Systems Europe, Abingdon, Oxon, UK). The intra- and inter-assay coefficients of variation were 2.5% and 7.0%, respectively, and the sensitivity of the test was 62 pg/mL.